Control Bionics Partners with Numotion

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 9, 2021:

Control Bionics and Numotion partnership will expand access those who can benefit from Control Bionics’ customized Augmentative and Alternative Communication (AAC) solutions.

Control Bionics‘ products help individuals dealing with a wide range of diagnoses, including ALS/MND, spinal muscular atrophy, cerebral palsy, and spinal cord injury. The Trilogy product line is a best-in-class option in the wider category of AAC devices, offering a customizable solution that complements a patient’s abilities as needs change over time alongside industry leading customer support.

“Control Bionics is passionate about helping clients find their ‘voice’ and regain control of their lives,” explained Neale Java, CFO at Control Bionics.  “We’re excited to be partnering with Numotion, an established company within the CRT space, to expand access to our life-changing, multi-modal communication solutions throughout the Northeast.”

While Numotion has more than 150 US locations, this partnership will be focused within the states of New Hampshire, Vermont, and New York to increase market awareness of the Control Bionics Trilogy Speech Generating Device as well as its best in class NeuroNode 3.0 sEMG (Electromyography) + Spatial sensor. This agreement is in line with Control Bionics’ growth strategy to access the larger rehab market and reinforces its commitment to provide industry-leading solutions with access to all.

“Adding Control Bionics’ Trilogy product line to our offering of AAC devices allows us to better serve those looking for flexible access methods and multi-modal solutions,” said Amanda Whipple, Director of Augmentative Communication at Numotion.”Their unique approach to AAC devices matches our desire to consistently improve and expand our offerings with cutting edge technology, ultimately offering the greatest benefit to our customers in need.”

Appointments are now available to begin the assessment process for Control Bionics’ products. Both Control Bionics and Numotion offer and support an extensive loan library of devices for clients and their clinicians wishing to trial this latest solution.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.